FPCG
CRVS icon

Fort Pitt Capital Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Fort Pitt Capital Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500
Closed -$2K – 171
2020
Q4 		$2K Buy
+500
New +$2.01K ﹤0.01% 339

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Fort Pitt Capital Group's CRVS Position: Q1 2021 in Review

Fort Pitt Capital Group sold out of Corvus Pharmaceuticals (CRVS) in Q1 2021, closing a stake of 500 shares — an estimated $2K sold.

Fort Pitt Capital Group first reported a position in CRVS in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 49 funds tracked by Wall St. Rank hold CRVS as of Q1 2021.

  • Fort Pitt Capital Group reported no remaining Corvus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Fort Pitt Capital Group sold 500 Corvus Pharmaceuticals shares in Q1 2021, an estimated $2K.
  • Fort Pitt Capital Group first reported a position in Corvus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Fort Pitt Capital Group's Corvus Pharmaceuticals position peaked at $2K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2021.

Based on Fort Pitt Capital Group's 13F filing for Q1 2021, filed 16 Apr 2021.